Aug. 4 at 11:55 AM
$RYTM Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of -
$0.73 up 2.67% YoY
• Reported revenue of
$71.25M up 46.91% YoY
• For the year ending December 31, 2026, Rhythm Pharmaceuticals anticipates approximately
$363 million to
$397 million in Non-GAAP Operating Expenses, which excludes stock-based compensation and fixed consideration related to in-licensing.
